

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Pharmaron Beijing Co., Ltd.**

**康龍化成(北京)新藥技術股份有限公司**

*(a joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 3759)**

**REDEMPTION OF  
US\$300.0 MILLION ZERO COUPON CONVERTIBLE BONDS DUE 2026  
(STOCK CODE: 40725)**

Reference is made to the announcements (the “**Announcements**”) of Pharmaron Beijing Co., Ltd. (the “**Company**”) dated June 8, 2021, June 9, 2021, June 11, 2021, June 18, 2021 and June 21, 2021 regarding the issuance of the US\$300.0 million zero coupon convertible bonds by the Company due 2026 (the “**Series 1 Bonds**”) and the announcements of the Company dated May 30, 2022, June 13, 2022, March 30, 2023, June 20, 2023, July 26, 2023 and January 12, 2024 regarding other matters related to the Series 1 Bonds, unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as those defined in the Announcements.

The Company hereby announces pursuant to the terms and conditions of the Series 1 Bonds, the Bondholders holding an aggregate principal amount of US\$218,900,000 of the Series 1 Bonds, representing approximately 72.97% of the aggregate principal amount of the Series 1 Bonds originally issued and approximately 99.32% of the current outstanding principal amount of the Series 1 Bonds, have exercised their option to require the Company to redeem all their Series 1 Bonds on June 18, 2024. As of the date of this announcement, all such Series 1 Bonds has been redeemed and cancelled, and the outstanding principal amount of Series 1 Bonds after the redemption is US\$1,500,000. Should the remaining US\$1,500,000 Series 1 Bonds be repurchased or redeemed by the Group, the Group will apply to The Stock Exchange of Hong Kong Limited for the withdrawal of the listing of the Series 1 Bonds and make an announcement in this regard.

The Company considers that there will be no material impact on the financial position of the Company as a result of the aforesaid redemption of the Series 1 Bonds.

By order of the Board  
**Pharmaron Beijing Co., Ltd.**  
康龍化成(北京)新藥技術股份有限公司  
**Dr. Lou Boliang**  
Chairman

Beijing, the PRC  
June 19, 2024

*As at the date of this announcement, the Board of Directors comprises Dr. Lou Boliang, Mr. Lou Xiaoqiang and Ms. Zheng Bei as executive Directors; Mr. Hu Baifeng and Mr. Li Jiaqing as non-executive Directors; Ms. Li Lihua, Mr. Zhou Qilin, Mr. Tsang Kwan Hung Benson and Mr. Yu Jian as independent non-executive Directors.*